BAUSCH LOMB IRELAND
PharmaBAUSCH LOMB IRELAND is a pharmaceutical company focused on Ophthalmology. Key products include FLUORESCEIN SODIUM AND BENOXINATE HYDROCHLORIDE.
BAUSCH LOMB IRELAND's Key Drugs
BAUSCH LOMB IRELAND's core commercial portfolio centers on FLUORESCEIN SODIUM AND BENOXINATE HYDROCHLORIDE, spanning Ophthalmology — its most strategically important drugs approved in the last 15 years.
BAUSCH LOMB IRELAND's Recent FDA Approvals
New NDA/BLA approvals for BAUSCH LOMB IRELAND over the last two years — novel drugs only, excluding generics and label supplements.
BAUSCH LOMB IRELAND's Therapeutic Areas
BAUSCH LOMB IRELAND's approved drugs and pipeline span 1 therapeutic area, led by Ophthalmology, across 0 biologic and 2 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
BAUSCH LOMB IRELAND's Top Competitors
BAUSCH LOMB IRELAND's closest competitors by therapeutic-area and drug-target overlap include Novartis, AbbVie, and OTSUKA ICU MEDCL. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
BAUSCH LOMB IRELAND Pipeline Snapshot
Active clinical trials for BAUSCH LOMB IRELAND across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • FLUORESCEIN SODIUM AND BENOXINATE HYDROCHLORIDE leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Ophthalmology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Discontinued (0)
Company Info
- First Approval
- 2000-04-12
- Latest
- 2023-02-12
- Applications
- 3